PMV Pharmaceuticals (PMVP) Operating Income (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Operating Income came in at -$19.0 million in Q1 2026, up 11.8% YoY from -$17.0 million in Q1 2025, and up 1.16% on a QoQ basis from -$19.2 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Operating Income (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of Operating Income data on file, last reported at -$19.0 million in Q1 2026.
- Quarterly Operating Income rose 11.8% year-over-year to -$19.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$83.7 million (up 5.78% YoY) and the FY2025 annual result came in at -$86.2 million, down 0.89% from the prior year.
- Operating Income rose to -$19.0 million in Q1 2026, from -$19.2 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$17.9 million in Q2 2022 to a low of -$25.2 million in Q4 2024.
- A 5-year average of -$20.5 million and a median of -$20.1 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income sank 59.49% — and 2025, when it rose 23.55%.
- Tracing PMVP's Operating Income over 5 years: stood at -$21.2 million in 2022, then increased by 10.68% to -$18.9 million in 2023, then sank by 33.15% to -$25.2 million in 2024, then climbed by 23.55% to -$19.2 million in 2025, then rose by 1.16% to -$19.0 million in 2026.
- The last three Operating Income figures came in at -$19.0 million (Q1 2026), -$19.2 million (Q4 2025), and -$22.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 133.12 Mn |
| 10 | PMV Pharmaceuticals | 70.47 Mn | -8.96 Mn | - | -18.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.02 Mn |
| Dec 31, 2025 | -19.24 Mn |
| Sep 30, 2025 | -22.52 Mn |
| Jun 30, 2025 | -22.88 Mn |
| Mar 31, 2025 | -21.56 Mn |
| Dec 31, 2024 | -25.17 Mn |
| Sep 30, 2024 | -21.89 Mn |
| Jun 30, 2024 | -20.17 Mn |
| Mar 31, 2024 | -18.22 Mn |
| Dec 31, 2023 | -18.90 Mn |
| Sep 30, 2023 | -19.63 Mn |
| Jun 30, 2023 | -20.12 Mn |
| Mar 31, 2023 | -21.48 Mn |
| Dec 31, 2022 | -21.16 Mn |
| Sep 30, 2022 | -19.38 Mn |
| Jun 30, 2022 | -17.89 Mn |
| Mar 31, 2022 | -18.62 Mn |
| Dec 31, 2021 | -18.47 Mn |
| Sep 30, 2021 | -15.10 Mn |
| Jun 30, 2021 | -13.05 Mn |